Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239710 | 0.90 | HIF1A (0.48) | HIF1ATYMPPOLBENPP1P2RY1 | |
| SCHEMBL13239719 | 0.86 | HIF1A (0.35) | HIF1ASLC29A1TYMP | |
| SCHEMBL25752702 | 0.85 | HIF1A (0.39) | HIF1ASLC29A1 | |
| SCHEMBL13239669 | 0.85 | SLC29A1 (0.42) | SLC29A1TYMP | |
| SCHEMBL30609212 | 0.84 | HIF1A (0.56) | HIF1ASLC29A1 | |
| SCHEMBL15171798 | 0.84 | HIF1A (0.56) | HIF1ASLC29A1 | |
| SCHEMBL26647666 | 0.84 | HIF1A (0.56) | HIF1ASLC29A1 | |
| SCHEMBL13239667 | 0.84 | HIF1A (0.56) | HIF1ASLC29A1 | |
| SCHEMBL15165612 | 0.81 | HIF1A (0.41) | HIF1ASLC29A1TYMPPOLBENPP1 | |
| SCHEMBL15171881 | 0.81 | HIF1A (0.35) | HIF1ASLC29A1TYMPP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | HIF1A 3959/4885SLC29A1 19/4885TYMP 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.